The Medicines Company (MDCO) Release: Data On Angiox (Bivalirudin Injection) In Heart Attack Patients Presented At Europcr And Published In European Heart Journal
5/22/2014 10:20:09 AM
PARIS--(BUSINESS WIRE)--During the Late Breaking Clinical Trial sessions at EuroPCR yesterday and published simultaneously in the European Heart Journal, Professor Uwe Zeymer of Klinikum Ludwigshafen, Ludwigshafen, Germany and others reported a paper entitled: “Bivalirudin is superior to heparins alone with bailout GP IIb/IIIa inhibitors in patients with ST-segment elevation myocardial infarction transported emergently for primary percutaneous coronary intervention: a pre-specified analysis from the EUROMAX trial”.
Help employers find you! Check out all the jobs and post your resume.
comments powered by